

Pain & Inflammation



SAMPLE ID
319773

SAMPLE NAME
Pain & Inflammation

MATRIX
Capsule

COLLECTED, RECEIVED
05/13/2021 10:34, 05/13/2021 10:34

SERVING SIZE, SERVINGS PER PACKAGE
1, 1

WEIGHT/VOLUME PER SERVING
535.63

CULTIVATOR INFO
CB Creative LLC

**TOTAL
CANNABINOIDS**

2605
MG PER SERVING

**TOTAL
THC**

ND
MG PER SERVING

**TOTAL
CBD**

2605
MG PER SERVING

Chemical Residue

Not Tested

NT

Residual Solvent

Not Tested

NT

Compliance Microbial

Not Tested

NT

Heavy Metals

Not Tested

NT

Mycotoxins

Not Tested

NT

Filth and Foreign Material

Not Tested

NT



CANNABINOID ANALYSIS

Total THC,CBD value(s) have been decarboxylated.

TOTAL THC: ND
 TOTAL CBD: 2605 mg per serving (4.863 mg/g) (0.4863 %), 2604.77 mg per package
 TOTAL CANNABINOIDS: 2605 mg per serving (4.863 mg/g) (0.4863 %)

UNIT OF MEASUREMENT: Milligrams per Gram(mg/g)


ANALYTE	RESULT	LOD	LLOQ	ANALYTE	RESULT	LOD	LLOQ
THCa	ND	0.0400	0.0800	CBDv	ND	0.0400	0.0800
D9THC	ND	0.0400	0.0800	CBGa	ND	0.0400	0.0800
D8THC	ND	0.0400	0.0800	CBG	ND	0.0400	0.0800
THCv	ND	0.0400	0.0800	CBN	ND	0.0400	0.0800
CBDa	ND	0.0400	0.0800	CBC	ND	0.0400	0.0800
CBD	4.863 mg/g (0.4863 %)	0.0400	0.0800				

ADDITIONAL INFORMATION

Method: SOP-TECH-001 Sample Prepped: 05/15/2021 10:27 Sample Approved: 05/17/2021 17:42
 Instrument: UPLC-DAD Sample Analyzed: 05/15/2021 13:12 Prep-Analytical Batch: 29402-23660

This report applies to the sample investigated and is not necessarily indicative of the quality or condition of apparently identical or similar products. This report provides technical results for a specific sample and the report shall not be altered, modified, supplemented, or abstracted in any manner. Any violation of these conditions renders the report and its results void. Furthermore, warning indications for analytes reported as 'ND' or '<LLOQ' on this COA are from data collected outside our validated ISO 17025 methodologies, and are only reported at the request of the customer. All LQC samples required by state regulations were performed and met the acceptance criteria.

THIS COA WAS REVIEWED AND APPROVED ON 05/17/2021 IN ACCORDANCE WITH REGULATORY REQUIREMENTS



Kayleen Sabino
 Executive Vice President of Operations